Multiple pharmaceutical companies are experiencing a "big harvest," with 20 companies doubling their net profits last year.

Securities Times Reporter Zang Xiaosong

Lisheng Pharmaceutical (002393) released its annual report on the evening of March 24. In 2025, the company achieved operating income of 1.392 billion yuan, a year-on-year increase of 4.18%; the net profit attributable to the parent company was 416 million yuan, a year-on-year increase of 125.59%; the basic earnings per share were 1.62 yuan. The company plans to convert every 10 shares into 2 additional shares and distribute a cash dividend of 6 yuan (tax included).

In 2025, Lisheng Pharmaceutical will deploy a “dual-driven” strategy of “industry + capital” to systematically promote the optimization and upgrading of the company’s industrial system towards high-end, intelligent, and green directions. During the reporting period, the company advanced the synergy of funds and direct investment, collaborating with CCB Equity to establish a pharmaceutical health special fund with an initial scale of 500 million yuan, creating a differentiated fund cluster. Meanwhile, it continuously explored high-quality investment targets along the upstream and downstream of the industrial chain, steadily advancing project reserve and selection work to solidify the resource foundation for future industrial expansion.

In 2025, China’s pharmaceutical industry enters a new stage characterized by “quality improvement, supply assurance, cost control, and correction,” presenting an overall trend of “slower growth, structural optimization, innovation leadership, and compliant development.” The three core forces of policy guidance, market demand, and technological change are deeply intertwined, accelerating the restructuring of the industrial landscape, which brings new challenges to industry development while creating structural development opportunities for leading enterprises with core competitiveness.

According to data from the National Bureau of Statistics, in 2025, the operating income of the national pharmaceutical manufacturing industry reached 2.487 trillion yuan, a year-on-year decrease of 1.2%; the total profit was 349 billion yuan, a year-on-year increase of 2.7%, showing a healthy operational trend of “slight revenue decline, stable profit.”

The Securities Times reporter found that as of the evening of March 24, 173 pharmaceutical companies had disclosed their “report cards” for 2025, of which 125 companies achieved profitability, and 20 companies had a net profit increase of over 100%.

Previously, on the evening of March 23, WuXi AppTec (603259) released its 2025 annual performance report: during the reporting period, the company achieved operating income of 45.456 billion yuan, a year-on-year increase of 15.84%; the net profit attributable to shareholders of the listed company was 19.151 billion yuan, with a year-on-year growth rate of 102.65%.

Tianyi Pharmaceutical (002728) achieved operating income of 925 million yuan last year, a year-on-year increase of 34.42%; the net profit attributable to the parent company was 81.6716 million yuan, a year-on-year increase of 298.5%. The company plans to distribute a cash dividend of 1.5 yuan (tax included) for every 10 shares to all shareholders.

Sihuan Pharmaceutical (688336) previously disclosed its performance forecast showing that in 2025, the company achieved operating income of 4.199 billion yuan, an increase of 251.81% from the previous year; the net profit attributable to the parent company was 2.939 billion yuan, an increase of 317.09% from the previous year. The company’s performance showed significant growth compared to the same period last year, mainly due to the important cooperation reached with Pfizer during the reporting period, where the company received an upfront payment for the 707 project from Pfizer and confirmed revenue of approximately 2.89 billion yuan accordingly.